CABALETTA BIO, INC. Gain (Loss) Related to Litigation Settlement
CABALETTA BIO, INC. (CABA) reported Gain (Loss) Related to Litigation Settlement of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Income Statement › Other Income
us-gaap:GainLossRelatedToLitigationSettlement · last filed 2022-08-11
- CABALETTA BIO, INC. gain (loss) related to litigation settlement for the quarter ending 2022-06-30 was $0.00.
- CABALETTA BIO, INC. gain (loss) related to litigation settlement for the quarter ending 2022-03-31 was $0.00.
- CABALETTA BIO, INC. gain (loss) related to litigation settlement for fiscal 2021 was $0.00.
| Period end | Gain (Loss) Related to Litigation Settlement 3 month | Gain (Loss) Related to Litigation Settlement 6 month | Gain (Loss) Related to Litigation Settlement 12 month |
|---|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | ||
| 2021-12-31 | $0.00 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |